Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
BACKGROUND: LMTM is being developed as a treatment for AD based on inhibition of tau aggregation. OBJECTIVES: To examine the efficacy of LMTM as monotherapy in non-randomized cohort analyses as modified primary outcomes in an 18-month Phase III trial in mild AD. METHODS: Mild AD patients (n = 800) were randomly assigned to 100 mg twice a day or 4 mg twice a day. Prior to unblinding, the Statistical Analysis Plan was revised to compare the 100 mg twice a day as monotherapy subgroup (n = 79) versus 4 mg twice a day as randomized (n = 396), and 4 mg twice a day as monotherapy (n = 76) versus 4 mg twice a day as add-on therapy (n = 297), with strong control of family-wise type I error. RESULTS: The revised analyses were statistically significant at the required threshold of p < 0.025 in both comparisons for change in ADAS-cog, ADCS-ADL, MRI atrophy, and glucose uptake. The brain atrophy rate was initially typical of mild AD in both add-on and monotherapy groups, but after 9 months of treatment, the rate in monotherapy patients declined significantly to that reported for normal elderly controls. Differences in severity or diagnosis at baseline between monotherapy and add-on patients did not account for significant differences in favor of monotherapy. CONCLUSIONS: The results are consistent with earlier studies in supporting the hypothesis that LMTM might be effective as monotherapy and that 4 mg twice a day may serve as well as higher doses. A further suitably randomized trial is required to test this hypothesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Fig.4 Annualized rate of whole brain atrophy (expressed as %) over months 0–6 and months 12–18 in monotherapy patients. The rates are compared with those reported by Leung et al. for mild AD and normal elderly controls [20].](https://figures.cochat.ai/paper-figures/aeac5f76d82b4c29866d5b5dc4b39bb2/potential-of-low-dose-leuco-methylthioninium-bis-hydromethanesulphonate-lmtm-figure-4.jpg)
![Fig.5 Voxel-based morphometric comparison showing regions of greater atrophy in patients receiving LMTM as monotherapy [N = 157] (A) or as add-on to approved treatments for AD [N = 610], (B) in TRx-237-005 compared with elderly controls [N = 244] from the ongoing Aberdeen birth cohort studies [23, 26], controlled for age, sex and total intracranial volume of each individual. (C) Voxel-based morphometric comparison of monotherapy and add-on patients in TRx-237-005. Data are displayed at a significance threshold corrected for family-wise error at the whole brain level at p < 0.05.](https://figures.cochat.ai/paper-figures/6e1dee94609a44d685c3236eb32611c9/potential-of-low-dose-leuco-methylthioninium-bis-hydromethanesulphonate-lmtm-figure-5.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Two earlier studies (NCT01689233 and NCT01689246) conducted on participants with mild AD and mild to moderate AD, respectively, indicated that the drug demonstrated good safety and potential benefits as a monotherapy.466,467”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [466]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 1×
“Tau protein has the capacity to form toxic proteolytically resistant oligomers which seed further tau aggregation in an autocatalytic manner [10] and propagate the pathology into previously healthy brain regions [11], most likely accounting for the stereotyped pattern of spread of pathology [6, 7, 12].”
BackgroundPosner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157 · cited 1×
“Patients were also assessed at all visits for suicidal ideation and intent using the Columbia-Suicide Severity Rating Scale [17], and were systematically monitored for potential serotonin syndrome using a rating scale derived from four published diagnostic criteria [18], because of a theoretical potential for serotoni…”
MethodA comparison of observational studies and randomized, controlled trials.
Benson, K., & Hartz, A. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006223422506 · Cited by 2,347
The clinical use of structural MRI in Alzheimer disease
Frisoni, G. B., Fox, N. C., Jack, C. R., Scheltens, P., & Thompson, P. M. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.215 · Cited by 2,113 · cited 1×
“In Alzheimer’s disease (AD), clinical deterioration [1], imaging markers of loss of neuronal function [2–4], and progression of brain atrophy as measured by MRI volumetry [5] progress in parallel with the accumulation of aggregated tau.”
BackgroundSelf-citationTwo Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · cited 3×
“as monotherapy or as add-on therapy was also compared with that reported for mild AD in the placebo arms of recent Phase III studies [21, 22] and currently available ADNI data (https://ida.”
ResultDefeating Alzheimer's disease and other dementias: a priority for European science and society
Winblad, B., Amouyel, P., Andrieu, S., Ballard, C., Brayne, C., Brodaty, H., Cedazo-Minguez, A., Dubois, B., Edvardsson, D., Feldman, H., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00062-4 · Cited by 1,676 · cited 1×
“Since measurable cohort differences in diagnosis or severity do not appear to explain the treatment differences we report, we believe that the within- and between-study consistency of the results cannot be dismissed lightly, particularly given the urgent need for new treatments in AD [56].”
Self-citationPhase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668 · cited 3×
“as monotherapy or as add-on therapy was also compared with that reported for mild AD in the placebo arms of recent Phase III studies [21, 22] and currently available ADNI data (https://ida.”
ResultAcetylcholine as a Neuromodulator: Cholinergic Signaling Shapes Nervous System Function and Behavior
Picciotto, M. R., Higley, M. J., & Mineur, Y. S. (2012) · Neuron · doi:10.1016/j.neuron.2012.08.036 · Cited by 1,404 · cited 1×
“Ascending cholinergic projections originating predominantly from nucleus basalis provide both direct activation [33] and indirect inhibitory modulation of cortical pyramidal cells [34].”
BackgroundAssociations between cognitive, functional, and FDG-PET measures of decline in AD and MCI
Landau, S. M., Harvey, D., Madison, C. M., Koeppe, R. A., Reiman, E. M., Foster, N. L., Weiner, M. W., & Jagust, W. J. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.07.002 · Cited by 750 · cited 5×
“Using the same methodology as in the ADNI program [24], baseline 18F-FDG-PET SUVR in inferior temporal gyrus normalized with respect to pons was less than that reported for mild AD [24] in both monotherapy (p = 0.”
BackgroundMethodResultInfluentialProteopathic tau seeding predicts tauopathy in vivo
Holmes, B. B., Furman, J. L., Mahan, T. E., Yamasaki, T. R., Mirbaha, H., Eades, W. C., Belaygorod, L., Cairns, N. J., Holtzman, D. M., & Diamond, M. I. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411649111 · Cited by 696
Research works printed but not linked: 1
- Gharid A, Atamna H (2011) Methylene blue induces mitochondrial complex IV and improves cognitive function and grip strength in old mice. In Neurodegeneration: Theory, Disorders and Treatments, McNeill AS, ed. AS Nova Science Publishers, Hauppauge, NY, pp. 63– 85.
Cited by
Items 101–200 of 221
Fang, G., Shi, B., Wu, K., Chen, S., Gao, X., Xiao, S., Kang, J. X., Li, W., & Huang, R. (2018) · International Journal of Neuroscience · doi:10.1080/00207454.2018.1533824 · Cited by 21
“achieved good results in phase III clinical trials [16,17].”
BackgroundTargeting the Electron Transport System for Enhanced Longevity
Radovic, M., Gartzke, L. P., Wink, S. E., van der Kleij, J. A., Politiek, F. A., & Krenning, G. (2025) · Biomolecules · doi:10.3390/biom15050614 · Cited by 17
Targets, trials and tribulations in Alzheimer therapeutics
Gharat, R., Dixit, G., Khambete, M., & Prabhu, A. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176230 · Cited by 19
Kim, S., Shin, S. J., Nam, Y., Park, Y. H., Kim, B., Park, H. H., Kumar, V., Yoo, D., Lee, Y. Y., Hoe, H., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.130516 · Cited by 20
Methylene Blue Blocks and Reverses the Inhibitory Effect of Tau on PMCA Function
Berrocal, M., Caballero-Bermejo, M., Gutierrez-Merino, C., & Mata, A. M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143521 · Cited by 17
“Since then, this dye has attracted increasing interest because of its use as a therapy to improve cognitive functions in AD patients [11,60,61], based on the fact that the formation of tau aggregates is involved in its toxicity and that inhibition of tau aggregation by MB may be linked to a reduction or loss of toxici…”
BackgroundResultThe Plasma Membrane Ca2+-ATPase, a Molecular Target for Tau-induced Cytosolic Calcium Dysregulation
Berrocal, M., & Mata, A. M. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.04.016 · Cited by 20
In Vivo Validation of a Small Molecule Inhibitor of Tau Self-Association in htau Mice
Davidowitz, E. J., Krishnamurthy, P., Lopez, P. L. D. C., Jimenez, H. T., Adrien, L. R., Davies, P., & Moe, J. G. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190465 · Cited by 19
Implications of Tau Dysregulation in Huntington’s Disease and Potential for New Therapeutics
Mees, I., Nisbet, R. M., Hannan, A. J., & Renoir, T. (2023) · Journal of Huntington s Disease · doi:10.3233/jhd-230569 · Cited by 16
Microtubule Dynamics Following Central and Peripheral Nervous System Axotomy
Kulkarni, R., Thakur, A., & Kumar, H. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00189 · Cited by 17
Lim, S., Shin, S., Sung, Y., Lee, H. E., Kim, K. H., Song, J. Y., Lee, G., Aziz, H., Lukianenko, N., Kang, D. M., et al. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-00959-5 · Cited by 17
Delbono, V., Larch, C. P., Newlands, K. C., Rhydderch, S., Baddeley, T. C., & Storey, J. M. D. (2022) · International Journal of Analytical Chemistry · doi:10.1155/2022/9171836 · Cited by 15
Self-citationten Kate, M., Barkhof, F., & Schwarz, A. J. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.92 · Cited by 15
Kondak, C., Riedel, G., Harrington, C. R., Wischik, C. M., & Klein, J. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15553 · Cited by 16
Self-citationNew Insights into Alzheimer’s Disease: Novel Pathogenesis, Drug Target and Delivery
Chen, H., Xu, J., Xu, H., Luo, T., Li, Y., Jiang, K., Shentu, Y., & Tong, Z. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041133 · Cited by 17
Topalis, V., Voros, C., & Ziaka, M. (2025) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887251361578 · Cited by 16
“294 ,295 Indeed, accumulating research has highlighted that patients with AD exhibit a disruption in glutamatergic neurotransmission and glutamate release, a key element for processes such as learning and memory.”
Experimental Disease-Modifying Agents for Frontotemporal Lobar Degeneration
Giunta, M., Solje, E., Gardoni, F., Borroni, B., & Benussi, A. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s262352 · Cited by 18
Бачурин, С. О., Shevtsova, E. F., Махаева, Г. Ф., Aksinenko, A. Y., Grigoriev, V. V., Горева, Т. В., Епишина, Т. А., Ковалева, Н. В., Boltneva, N. P., Lushchekina, S. V., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213925 · Cited by 15
Mackey-Alfonso, S. E., & Barrientos, R. M. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70911 · Cited by 15
Apathy-like behaviour in tau mouse models of Alzheimer’s disease and frontotemporal dementia
Robinson, L., Dreesen, E., Mondésir, M., Harrington, C. R., Wischik, C. M., & Riedel, G. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114707 · Cited by 15
“Despite the absence of appropriate tests and definitions, apathy is increasingly diagnosed as a behavioural symptom in dementia [11,12].”
Self-citationBenetik, S. F., Knez, D., Obreza, A., Košak, U., & Gobec, S. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108748 · Cited by 15
Molecular Insights into Tau Pathology and its Therapeutic Strategies in Alzheimer's Disease
Zhou, F., Zhao, Y., Sun, Y., & Chen, W. (2024) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2311197 · Cited by 15
“Another study [145], however, did support the notion that LMTM could be effective as monotherapy.”
Riluzole and Its Prodrugs for the Treatment of Alzheimer’s Disease
Al‐Horani, R. A. (2023) · Pharmaceutical Patent Analyst · doi:10.4155/ppa-2023-0001 · Cited by 13
Zadrożny, M., Drapich, P., Gąsiorowska, A., Niewiadomski, W., Harrington, C. R., Wischik, C. M., Riedel, G., & Niewiadomska, G. (2024) · Cells · doi:10.3390/cells13070642 · Cited by 14
“This reduction in the pharmacological efficacy of HMTM, when given as an add-on to symptomatic treat-ment in humans, was observed in several other studies using the L1 tau model [15,34] and in clinical trials [5,61].”
BackgroundMethodResultInfluentialSelf-citationInsights for Alzheimer's disease pharmacotherapy and current clinical trials
do Nascimento, A. L. C. S., Fernandes, R. P., Carvalho, A. C. S., Frigieri, I., Alves, R. C., & Chorilli, M. (2022) · Neurochemistry International · doi:10.1016/j.neuint.2022.105401 · Cited by 14
Hepta-Histidine Inhibits Tau Aggregation
Kondo, K., Ikura, T., Tanaka, H., Fujita, K., Takayama, S., Yoshioka, Y., Tagawa, K., Homma, H., Liu, S., Kawasaki, R., et al. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00164 · Cited by 14
Pharmacotherapeutic combinations for the treatment of Alzheimer’s disease.
Nagata, T., Shinagawa, S., Nakajima, S., Noda, Y., & Mimura, M. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2042514 · Cited by 11
Recent Updates on the Development of Therapeutics for the Targeted Treatment of Alzheimer’s Disease
Rajput, S., Malviya, R., Bahadur, S., & Puri, D. (2023) · Current Pharmaceutical Design · doi:10.2174/0113816128274618231105173031 · Cited by 13
Wischik, C. M., Stefanacci, R. G., Bentham, P., Gauthier, S. G., Zetterberg, H., Wilcock, G. K., Froelich, L., Burns, A. S., MacSweeney, E., Ballard, C. G., et al. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100480 · Cited by 14
Self-citationLye, S., Aust, C. E., Griffiths, L. R., & Fernandez, F. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.117332 · Cited by 11
Schwab, K., Melis, V., Harrington, C. R., Wischik, C. M., Magbagbeolu, M., Theuring, F., & Riedel, G. (2021) · Cells · doi:10.3390/cells10082162 · Cited by 11
“LMTM is being developed as a treatment targeting pathological aggregation of tau protein in AD and FTD [48,49,90,91], and this strategy appears promising since a correlation between the degree of tau aggregation and the severity of dementia has been established [12,13,37,45].”
BackgroundSelf-citationPerspectives on drug discovery strategies based on IDPs
Fuertes, G., Nevola, L., & Esteban-Martín, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816348-1.00009-0 · Cited by 15
Tau immunotherapy in Alzheimer’s disease and progressive supranuclear palsy
Karimi, N., Catak, F. B., Arslan, E. O., Saghazadeh, A., & Rezaei, N. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109445 · Cited by 13
Chinnathambi, S., Dubey, T., & Chandrashekar, M. (2023) · Cellular Physiology and Biochemistry · doi:10.33594/000000621 · Cited by 10
Beyond amyloid plaque, targeting α-synuclein in Alzheimer disease: The battle continues
Al-Kuraishy, H. M., Sulaiman, G. M., Mohammed, H. A., Al-Gareeb, A. I., Albuhadily, A. K., Ali, A. A., & Abu-Alghayth, M. H. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102684 · Cited by 11
Targeting tau in Alzheimer’s Disease: rationale, approach and challenges
Aslanyan, A., Foiani, M. S., Giovannucci, T. A., McDade, E., Duff, K., Mummery, C. J., Schöll, M., Wildsmith, K. R., & Paterson, R. W. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00925-5 · Cited by 10
“Phase 3 trials in humans showed no safety concerns [205, 206] and although the initial results were reported to show no overall differences in the clinical or neuro-imaging outcomes, it was later suggested that the lack of clinical difference was due to combination activity of hydromethylthionine…”
Recent Advancements in Strategies for Abnormal Protein Clearance in Alzheimer's Disease
Zhuang, J., Gao, J., Yin, Y., Gong, B., Ji, W., Chen, X., Li, P., Cheng, W., Zhao, Y., & He, B. (2022) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557522666220214092824 · Cited by 11
Singh, N., MacNicol, E., Dipasquale, O., Randall, K., Lythgoe, D. J., Mazibuko, N., Simmons, C., Selvaggi, P., Stephenson, S., Turkheimer, F., et al. (2023) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x231157958 · Cited by 10
A Machine Learning Approach to Predict Cognitive Decline in Alzheimer Disease Clinical Trials
Nallapu, B. T., Petersen, K. K., Qian, T., Demirsoy, İ., Ghanbarian, E., Davatzikos, C. A., Lipton, R. B., Ezzati, A., Initiative, A. D. N., Weiner, M. W., et al. (2025) · Neurology · doi:10.1212/wnl.0000000000213490 · Cited by 10
Afrakoti, L. G. M. P., Moghadam, S. D., & Hadinezhad, P. (2025) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823251329188 · Cited by 16
“242 The fi rst monoclonal antibodies entered in the phase III clinical trial were bapineuzumab and solanezu-mab.”
Twenty years of therapeutic development in tauopathy mouse models: a scoping review
Langness, V. F., Simmons, D. A., McHugh, T. L. M., Butler, R. R., Zhou, J., Liu, H., Yang, T., Ellerby, L., & Longo, F. M. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70578 · Cited by 9
Zheng, X., Tang, Y., Yang, Q., Wang, S., Chen, R., Tao, C., Zhang, P., Fan, B., Zhan, J., Tang, C., et al. (2022) · Journal of the American Geriatrics Society · doi:10.1111/jgs.18025 · Cited by 10
Kammula, S. V., Tripathi, S., Wang, N., Dawson, V. L., Dawson, T. M., & Mao, X. (2023) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2023.20 · Cited by 16
Current trends and updates in the treatment of Alzheimer's disease
Parikh, N. H., Parikh, P. K., Rao, H. J., Shah, K., Dave, B. P., & Prajapati, B. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13205-6.00014-5 · Cited by 9
Zhao, L., Cheng, X., & Zhong, C. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00450 · Cited by 9
Deep brain stimulation of the nucleus basalis of Meynert in severe Alzheimer’s disease
Xu, J., Liu, B., Shang, G., Liu, S., Feng, Z., Yang, H., Liu, D., Chang, Q., Chen, Y., Yu, X., et al. (2024) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823241296780 · Cited by 9
“29,30 Phase II clinical trials of second-generation tau protein aggregation inhibitors TRx0237, gosuranemab, tilavonemab, and zagotenemab have shown no clinical bene fi t for patients withmildADandhavenotachievedthe purposeofimproving cognitive function.”
Santos, R. X., Melis, V., Goatman, E. A., Leith, M., Baddeley, T. C., Storey, J. M. D., Riedel, G., Wischik, C. M., & Harrington, C. R. (2022) · Biomedicines · doi:10.3390/biomedicines10040867 · Cited by 9
“In phase 3 clinical trials testing hydromethylthionine in AD, the disease progression was slowed in patients taking HMTM as a monotherapy but not in patients already taking standard symptomatic drugs approved for the treatment of AD (acetylcholinesterase inhibitors and/or glutamatergic inhibitors) [36,37].”
BackgroundMethodInfluentialSelf-citationPanda, S. P., Prasanth, D., Gorla, U. S., & Dewanjee, S. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101783 · Cited by 8
Tau-based therapies for Alzheimer’s disease: Promising novel neuroprotective approaches
Sayas, C. L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814037-6.00005-7 · Cited by 11
Wu, J., Geng, C., Liu, L., & Tang, Y. (2025) · Medicine Plus · doi:10.1016/j.medp.2025.100112 · Cited by 9
Intrinsically disordered proteins and liquid–liquid phase separation in drug discovery
Deka, N., Nag, N., & Tripathi, T. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104603 · Cited by 10
Krankheitsmodifizierende Therapieansätze bei Alzheimer-Krankheit
Frölich, L., & Hausner, L. (2021) · Der Nervenarzt · doi:10.1007/s00115-021-01222-w · Cited by 13
“Eine Phase-3-Studie zu dem Aggregationshemmer TRx0237 läuft derzeit noch [33].”
BackgroundR-carvedilol, a potential new therapy for Alzheimer’s disease
Yao, J., & Chen, S. R. W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1062495 · Cited by 11
“For example, a molecule named leucomethylthioninium bis(hydromethanesulphonate) (LMTM) that is thought to block the aggregation of tau has been shown to possess some promising anti-AD properties in a phase III clinical trial (Wilcock et al., 2018).”
BackgroundXue, W., He, W., Yan, M., Zhao, H., & Pi, J. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230559 · Cited by 6
“Basedonthe currentunderstandingofADmechanisms,existing clinicaldrugstudieshavefocusedonamyloidosis andpathologicaltau[14–19].”
Xu, J., Liu, B., Feng, Z., Yu, X., Shang, G., Liu, Y., Sun, Y., Yang, H., Chen, Y., Zhang, Y., et al. (2024) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823241297852 · Cited by 7
“…18 – 22 which remove A β protein; methylene blue, which inhibits the aggregation and formation of tau protein (leuco-methylthioninium bis, LMTM) 23,24 ; vaccine AADvac1 that clears pathological tau protein in the brain 25,26 ; drugs that inhibit neuroin fl am-mation such as daratumumab, NE3107,…”
Fungally Derived Isoquinoline Demonstrates Inducer-Specific Tau Aggregation Inhibition
Ingham, D. J., Blankenfeld, B. R., Chacko, S., Perera, C., Oakley, B. R., & Gamblin, T. C. (2021) · Biochemistry · doi:10.1021/acs.biochem.1c00111 · Cited by 6
Yin, H., Han, Y.-L., Yan, X. H., & Guan, Y. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.126140 · Cited by 6
Schwab, K., Lauer, D., Magbagbeolu, M., Theuring, F., Gąsiorowska, A., Zadrożny, M., Harrington, C. R., Wischik, C. M., Niewiadomska, G., & Riedel, G. (2024) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2024.110955 · Cited by 6
“…symptomatic treatment with AChEI (e.g., rivastigmine, donepezil or galant-amine) and / or the NMDA receptor antagonist memantine, while it produced significant arrest of cognitive and functional decline in subjects receiving the drug as monotherapy (Gauthier et al., 2016; Wilcock et al., 2018).”
BackgroundSelf-citationEmerging drugs for progressive supranuclear palsy
Giagkou, N., & Stamelou, M. (2019) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2019.1609450 · Cited by 6
Alzheimer’s Disease Pharmacology
Plascencia‐Villa, G., & Perry, G. L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00018-9 · Cited by 8
Robinson, L., Bray, J. G., Melis, V., Harrington, C. R., Wischik, C. M., & Riedel, G. (2025) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000865 · Cited by 5
“In phase 3 clinical trials, HMTM slowed the cognitive decline in AD patients, although the efficacy was decreased in participants who had already been receiving symptomatic medications such as ChEIs (Gauthier et al ., 2016; Wilcock et al ., 2017).”
Self-citationMitochondrial Effects of Hydromethylthionine, Rivastigmine and Memantine in Tau-Transgenic Mice
Kondak, C., Leith, M., Baddeley, T. C., Santos, R. X., Harrington, C. R., Wischik, C. M., Riedel, G., & Klein, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310810 · Cited by 5
“There were no differences between high and low doses in either of the two trials [20,21].”
ResultInfluentialSelf-citationDesign and application of a Tau seed amplification assay for screening inhibitors of Tau seeding
Gorski, D., Evans, H., Allison, T., Barria, C., Harrison, D., Banerjee, V., Méndez, N., Shahnawaz, M., Kaalund, S. S., Folke, J., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01855-y · Cited by 6
Emmerson, J. T., Carmo, S. D., Lavagna, A., Huang, C., Wong, T. P., Martínez-Trujillo, J., & Cuello, A. C. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01901-0 · Cited by 5
Comprehending Alzheimer's Disease: Molecular Mechanisms and Treatment Strategies
Rathee, S., Pandey, V., Soni, S., Sen, D., & Jain, S. (2025) · Current Alzheimer Research · doi:10.2174/0115672050368798250626075628 · Cited by 8
Potential role of Drug Repositioning Strategy (DRS) for management of tauopathy
Zaki, M. O., Elsherbiny, D. A., Salama, M., & Azab, S. S. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.120267 · Cited by 7
Micheau, J., Catheline, G., Barse, E., Hiba, B., Marcilhac, A., Allard, M., Platt, B., & Riedel, G. (2024) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2024.111161 · Cited by 4
Self-citationNing, Q., Liu, J., Zhu, X., Liu, S., Zou, Q., Li, Z., & Li, Z. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114610 · Cited by 5
Kang, D. M., Lukianenko, N., Baik, J., Kim, Y. K., & Lim, S. (2025) · ChemBioChem · doi:10.1002/cbic.202500316 · Cited by 4
Huang, Y., Chan, H., Khoo, J.-Y., Chan, M.-L., Bender, D. A., Ponnusamy, V. K., Belaidi, A. A., & Ke, L. (2025) · Neurochemistry International · doi:10.1016/j.neuint.2025.106104 · Cited by 4
Advances in Diagnostics and Treatments for Alzheimer’s Disease
Sunderland, A., Thatcher, A. L., Rackley, E. V., & Kuruvilla, T. (2025) · British Journal of Hospital Medicine · doi:10.12968/hmed.2025.0492 · Cited by 4
Elbermawy, Y., El-Desouky, S., Arafa, R. K., Elfarrash, S., & Bassiouny, A. R. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05534-9 · Cited by 5
“Clinical studies reported slowed brain atrophy rates and stabilization of cognitive decline in monotherapy subgroups [82], but phase III outcomes were variable, and higher doses caused tolerability issues such as gastrointestinal, urinary adverse effects, and severe toxicity [27, 41, 61, 68].”
Small molecules to target tau amyloid aggregation
Manglano-Artuñedo, Z., Peña‐Díaz, S., & Ventura, S. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.380900 · Cited by 4
“In a Phase III study, LMTM monotherapy administration showed promising results in mild AD patients, moderately enhancing brain atrophy (Wilcock et al., 2018).”
BackgroundSchwab, K., Robinson, L., Annschuetz, A., Dreesen, E., Magbagbeolu, M., Melis, V., Theuring, F., Harrington, C. R., Wischik, C. M., & Riedel, G. (2024) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2024.111172 · Cited by 4
“However, this efficacy is not seen with subjects who have already been receiving symptomatic treatments (Baddeley et al., 2015; Gauthier et al., 2016; Wilcock et al., 2018; Schelter et al., 2019; Shiells et al., 2020).”
Self-citationTripathi, S. M., McNeil, C. J., Staff, R. T., Murray, A. D., Wischik, C. M., Schelter, B. O., & Waiter, G. D. (2025) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-025-00908-2 · Cited by 5
Self-citationKazkayası, İ., & Telli, G. (2024) · Biology Bulletin · doi:10.1134/s106235902360455x · Cited by 4
Enhanced monitoring of Alzheimer's disease brain atrophy using composite value ratios of volumes
Saguer, I. L., & Oxtoby, N. P. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf497 · Cited by 3
“14 15-17 .”
In Vitro and In Vivo Evaluation of Small-Molecule Disassemblers of Pathological Tau Fibrils
Pan, H., Cheng, X., Zhang, J., Hou, K., Murray, K. A., Manglani, K., Zhu, C., Hsu, H., Mekkittikul, M., Halladay, T., et al. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00940 · Cited by 4
Intravitreally Injected Methylene Blue Protects Retina against Acute Ocular Hypertension in Rats
Ye, Z., Li, X., Zheng, D., Pei, S., Cheng, P. F., Zhang, L., & Zhu, L. J. (2021) · Current Eye Research · doi:10.1080/02713683.2021.1948062 · Cited by 3
Hydromethylthionine sustains truncated tau‐dependent inflammation‐lowering effects in mouse brain
Santos, R. X., Lee, S. H., Lofthouse, R. A., Melis, V., Robinson, L., Leith, M., Dreesen, E., Armstrong, P., Vorley, T., Goatman, E. A., et al. (2025) · FEBS Journal · doi:10.1111/febs.70021 · Cited by 3
“Since it was previously reported that symptomatic therapies for dementia interfered with the disease-slowing effects of HMTM in AD [30], we at the same time investigated whether memantine could sustain any long-term effects in brain inflammation and/or negatively impact on the effects of HMTM…”
InfluentialSelf-citationSaini, M., Rohilla, S., & Kumar, R. (2025) · Current Aging Science · doi:10.2174/0118746098376646250715094707 · Cited by 3
The Therapeutic Effects of Seven Lycopodium Compounds on Cell Models of Alzheimer’s Disease
Guo, Q., Cai, Q., Huang, F., Wei, Z. C., Wang, J., Zhang, B., Liu, R., Yang, Y., Wang, X., & Li, H. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220704 · Cited by 3
Park, H. H., Kim, B., Leem, S. H., Park, Y. H., Chung, H., Yoo, D., Park, I., Nam, Y., Kim, S., Shin, S. J., et al. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673295901240311072440 · Cited by 2
Decoding physical environment's role in protein phase transition
Ge, W., & Yin, D. (2025) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2025.103643 · Cited by 2
van Maanen, E., Gonçalves, A., Chen, L., Fauchet, F., Cristea, S., Smith, J., Baddeley, T., Shiells, H., Hewitt, F., Schelter, B. O., et al. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70539 · Cited by 3
“10,11 After the double-blind period, all participants received open-label HMTM 16 mg/day for another 12 months.”
Self-citationHasan, M., Abd-Elraouf, K., Moran, S. R., & Lo, C. H. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27125467 · Cited by 2
“However, multiple Phase III trials in patients with mild-to-moderate AD failed to show clear clinical benefit [119,120].”
Pharmacotherapy for Alzheimer’s disease: what’s new on the horizon?
Khoury, R., Gallop, A., Roberts, K., Grysman, N., Lu, J., & Grossberg, G. T. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2097868 · Cited by 2
“ADAS-Cog and ADCS-ADL, in post-hoc analyses [93].”
Bentham, P., Staff, R. T., Schelter, B. O., Shiells, H., Harrington, C. R., & Wischik, C. M. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210390 · Cited by 2
“Therefore, 8 mg/day is the minimum effective dose of LMTM in both AD and bvFTD [12, 20], although the predicted optimum doses differ: 16 mg/day in AD and 20–60 mg/day in bvFTD.”
BackgroundResultSelf-citationTau Pathology and Neurodegenerative Disorders
Takashima, A., Soeda, Y., Koike, R., & Maeda, S. (2022) · Springer eBooks · doi:10.1007/978-981-16-7977-3_22 · Cited by 2
Frontotemporal lobar degeneration
Kim, B., Viera-Ortiz, A., Phan, J. M., Irwin, D. J., & Lee, E. B. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85654-6.00041-1 · Cited by 3
Therapeutic approaches in proteinopathies
Nabi‐Afjadi, M., Dabirmanesh, B., & Uversky, V. N. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.03.008 · Cited by 4
Tripathi, S. M., Shiells, H., Waymont, J. M. J., Staff, R. T., Schelter, B. O., Bentham, P., Wischik, C. M., & Murray, A. D. (2026) · Current Alzheimer Research · doi:10.2174/0115672050399596251106033110 · Cited by 2
Self-citationAhmad, H. A., Zafar, M., Khan, T., & Khan, M. I. (2026) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-026-05505-1 · Cited by 2
“However, multiple Phase III trials in mild-to-moderate AD failed to show clinical efficacy for LMTX when given as an add-on to standard therapy [ 64 ] .”
Jang, K.-B., Kang, D., Lee, M.-H., Lukianenko, N., Kim, Y. K., Lim, S., Kim, S., & Cho, H. J. (2026) · Scientific Reports · doi:10.1038/s41598-026-42195-7 · Cited by 1
“However, no significant reduction in functional decline has been observed in subjects with mild to moderate AD in the trials 56,57 .”
Zhang, H., Liu, C., Yuan, X., & Yin, H. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1818913 · Cited by 2
Monoclonal antibodies and small molecules: on the cutting edge of Alzheimer’s disease therapy
Ouro, A., Ben-Dor, G. A., Debasa‐Mouce, M., Gulkarov, S., Leon, J. D., Castro‐Mosquera, M., Sobrino, T., Bougea, A. M., & Reiss, A. B. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1766762 · Cited by 1
“The brain atrophy rate in patients on the monotherapy demonstrated a significant decline after 9 months of LMTM monotherapy (Wilcock et al., 2018).”
Current Advancements in the Treatment of Alzheimer’s Disease
Ajith, V., & Kalam, A. (2022) · Journal of Student Research · doi:10.47611/jsrhs.v11i4.3691 · Cited by 1
Drug discovery in Alzheimer’s disease by regulating autophagy
Hamano, T., & Endo, Y. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-89906-2.00002-2 · Cited by 1
Present and Future Therapies for Alzheimer’s Disease
Nagase, H., & Nakayama, K. (2018) · InTech eBooks · doi:10.5772/intechopen.75449 · Cited by 1
“[71] Wilcock GK, Gauthier S, Frisoni GB, Jia J, Hardlund JH, Moebius HJ, Bentham P, Kook KA, Schelter BO, Wischik DJ, Davis CS, Staff RT, Vuksanovic V, Ahearn T, Bracoud L, Shamsi K, Marek K, Seibyl J, Riedel G, JMD S, Harrington CR, Wischik CM.”
BackgroundA study of the global effects of Apolipoprotein E using lipidomics
Hawksworth, J. I. (2019) · ORCA Online Research @Cardiff (Cardiff University)
Dubey, T., Gorantla, N. V., & Chinnathambi, S. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.06.980276
“Methylene blue derived Leuco-methylthioninium Bis (Hydromehanesulphonate) (LMTM) entered phase-3 clinical trial for treatment of mild Alzheimer’s disease(Wilcock et al. 2018), (which was not certified by peer review) is the author/funder.”
Background
Metadata
- Authors
- Wilcock, G. K., Gauthier, S., Frisoni, G. B., Jia, J., Hardlund, J. H., Moebius, H. J., Bentham, P., Kook, K. A., Schelter, B. O., Wischik, D. J., Davis, C. S., Staff, R. T., Vuksanovic, V., Ahearn, T., Bracoud, L., Shamsi, K., Marek, K., Seibyl, J., Riedel, G., Storey, J. M. D., Harrington, C. R., & Wischik, C. M.
- Affiliations
- University of Oxford (GB)
- Douglas Mental Health University Institute (CA)
- University of Geneva (CH)
- Beijing Institute for Brain Disorders (CN)
- TauRx (United Kingdom) (GB)
- Moebius-Consult, Baar, Switzerland
- Birmingham and Solihull Mental Health NHS Foundation Trust (GB)
- Salamandra LLC, Bethesda, MD, USA
- University of Aberdeen (GB)
- University of Cambridge (GB)
- CSD Biostatistics, Tucson, AZ, USA
- Aberdeen Biomedical Imaging Centre, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK
- BioClinica, Lyon, France
- RadMD, New York, NY, USA
- MNI Imaging, New Haven, CT, USA
- Corresponding author
- Wischik, Claude M.
- ORCID
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2017-11-28
- Volume
- 61
- Issue
- 1
- Pages
- 435-457
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC5734125
- OpenAlex
- W2768871557
- Cited by
- 219
- References
- 57
- Citations by year
- 2026: 16 · 2025: 26 · 2024: 30 · 2023: 31 · 2022: 28 · 2021: 27 · 2020: 27 · 2019: 17 · 2018: 16 · 2017: 1
- FWCI
- 12.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion)
- Aberdeen University Research Archive (Aberdeen University) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Funders
- TauRx Pharmaceuticals
- European Commission
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- MeSH terms
- Mental Status and Dementia Tests, Aged, Aged, 80 and over, Alzheimer Disease, Double-Blind Method, Female, Humans, International Cooperation, Male, Methylene Blue, Middle Aged, Antipsychotic Agents, Cohort Studies, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.